Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2017 · 10-K
Revenue$60.40M$60.40M−4.9% vs Q4 2016 Net Income$1.47M$1.47MN/M vs Q4 2016 EPS Diluted$0.02$0.02N/M vs Q4 2016 Gross Profit$20,490,000+2.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$9,765,000−30.3% Free Cash Flowderived-$353,000N/M Margins · derivedGross margin33.9%+2.5 pt vs Q4 2016
Operating margin-3.2%+4.4 pt vs Q4 2016
Net margin2.4%+6.7 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 14, 2018 · 73 d after period end